The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...

Gepotidacin is the first new class of oral antibiotics for uUTIs in nearly 30 years, addressing rising drug resistance. Phase 3 trials showed gepotidacin's non-inferiority to nitrofurantoin ...

Blujepa (gepotidacin) is the first new antibiotic class approved in nearly 30 years ... In these studies, Blujepa was compared with nitrofurantoin, a leading treatment for uncomplicated UTIs.

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.

Results of two phase III trials -- EAGLE-2 and EAGLE-3-- supported approval, demonstrating that the first-in-class antibiotic was noninferior to nitrofurantoin, a standard option for uncomplicated ...

“We are proud to have developed Blujepa, the first in a new class of oral antibiotics ... as well as or better than nitrofurantoin, the frontline antibiotic which is currently used to treat ...

In the EAGLE-3 experiment, gepotidacin was statistically superior to nitrofurantoin. “As a first-in-class investigational oral antibiotic with activity against common uropathogens, including ...

Blujepa sets itself apart from nitrofurantoin as ... To put it simply, the drug is designed to specifically inhibit bacterial DNA in the E. coli class, which causes the majority of UTI infections ...

47% in patients treated with nitrofurantoin ... the first in a new class of oral antibiotics for uUTIs in nearly three decades, and to bring another option to patients given recurrent infections ...